INGELHEIM, Germany & VIENNA--(BUSINESS WIRE)--Results from the VERxVE study presented today at the 18th International AIDS Society (IAS) conference in Vienna, Austria, show that once daily nevirapine extended release (XR) formulation (400mg QD) Viramune® is non-inferior to the currently used twice daily immediate release (200mg BID) Viramune® (IR) through 48 weeks.
